-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
CompilationFan Dongdong
In the field of pharmaceutical research and development, the road to effective and approved drugs is usually paved by failures.
A few days ago, the research and development of Merck’s HIV project suffered a major blow.
Although Merck was quick to point out the cause of MK-8507, islatravir may also play a role in it
Currently, Merck has stopped the drug in the trial and will continue to monitor 161 study participants
This combination therapy is intended as a weekly treatment.
In addition to Merck, another American company Enanta also felt the sting of the failure of the HBV trial program
This result is somewhat surprising, however, because the drug had "demonstrated a comprehensive toxicology studies with a pre-clinical safety profile"
However, the company said it will continue to work on the development of functional cures for patients with chronic hepatitis B, and maintain confidence in its core product, HBV inhibitor EDP-514, which is effective in viremia and NUC-inhibited chronic HBV patients in stage 1b.
Just last month, Enanta also cancelled two clinical-stage NASH treatments under development, although the Phase IIb data showed some promise
Reference source:
1.
2.
